NMD_Logo3_reg.jpg
NMD Pharma Receives FDA IND Clearance to initiate a Phase 2b Clinical Trial of NMD670 in Generalized Myasthenia Gravis Patients in the US
March 22, 2024 07:00 ET | NMD Pharma
NMD Pharma Receives FDA IND Clearance to initiate a Phase 2b Clinical Trial of NMD670 in Generalized Myasthenia Gravis Patients in the US Aarhus, Denmark, 22 March 2024 – NMD Pharma A/S, a...
NMD_Logo3_reg.jpg
NMD Pharma Receives FDA IND Clearance to initiate a Phase 2b Clinical Trial of NMD670 in Generalized Myasthenia Gravis Patients in the US
March 22, 2024 02:00 ET | NMD Pharma
NMD Pharma Receives FDA IND Clearance to initiate a Phase 2b Clinical Trial of NMD670 in Generalized Myasthenia Gravis Patients in the US Aarhus, Denmark, 22 March 2024 – NMD Pharma A/S, a...
NMD_Logo3_reg.jpg
NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine
March 21, 2024 07:00 ET | NMD Pharma
NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine ClC-1 is a chloride ion channel specifically expressed in skeletal muscle cells that normally dampens...
NMD_Logo3_reg.jpg
NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine
March 21, 2024 02:00 ET | NMD Pharma
NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine ClC-1 is a chloride ion channel specifically expressed in skeletal muscle cells that normally dampens...
Myasthenia Gravis Treatment Market Will Experience Growth, Reaching US$4.1 Billion by the End of 2030, Predicts Persistence Market Research
January 23, 2024 01:45 ET | Persistence Market Research
New York, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Myasthenia Gravis Treatment Market Poised for Steady Growth, driven by Innovation and Rising Awareness The global market for myasthenia gravis (MG)...
Global Myasthenia Gravis Treatment Market
Global Myasthenia Gravis Treatment Market Forecast and Trends 2023-2028, Featuring Profiles of AbbVie, Bausch Health, Gilead Sciences, Merck, Servier and Teva
December 18, 2023 06:43 ET | Research and Markets
Dublin, Dec. 18, 2023 (GLOBE NEWSWIRE) -- The "Global Myasthenia Gravis Treatment Market: Forecast and Trends" report has been added to ResearchAndMarkets.com's offering. The global market for...
Myasthenia Gravis Treatment Market
Myasthenia Gravis Treatment Market Size, Share & Growth Analysis, [2028] | With CAGR of 7.5%
December 06, 2023 07:28 ET | Fortune Business Insights
Pune, India, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Global Myasthenia Gravis Treatment Market Size was valued at USD 1.15 billion in 2020 and is projected to grow from USD 2.03 billion by 2028 exhibiting...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE®
November 02, 2023 10:37 ET | Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Logo.png
Myasthenia Gravis Market is Projected to Boost at a Moderate Growth Rate by 2032, Estimates DelveInsight | Leading Companies - DAS-MG, Catalyst, Cabaletta Bio, Janssen, Argenx, UCB Pharma, Alexion, Immunovant
October 25, 2023 13:00 ET | DelveInsight Business Research LLP
New York, USA, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Myasthenia Gravis Market is Projected to Boost at a Moderate Growth Rate by 2032, Estimates DelveInsight | Leading Companies - DAS-MG, Catalyst,...
What’s on Your Must-
What’s on Your Must-Read List? If You Work in Pharma, Add Spherix Global Insights’ Generalized Myasthenia Gravis Patient Chart Audit to that List
August 10, 2023 15:15 ET | Spherix Global Insights
Exton, Pennsylvania, Aug. 10, 2023 (GLOBE NEWSWIRE) -- In one of the largest patient-focused studies ever conducted in gMG, Spherix’s RealWorld Dynamix™: Treatment Patterns in generalized Myasthenia...